title: Personalized antipsychotic treatment: the adverse effects perspectives.
abstract: Antipsychotics are the lodestar in the treatment of schizophrenia despite the variability of the therapeutic response and drug-induced adverse effects (especially extrapyramidal symptoms, gain weight, and metabolic disturbances). More and more data are supporting the notion that genetic factors - as well as often overlooked personal and environmental factors - that define the inter-individual differences in pharmacokinetic and pharmacodynamic treatment response. At present, there are no practical pharmakogenetic tests that could be used in everyday clinical practice; however, in the field of psychiatry they are expected within a few years. Pharmacogenetic tests will indubitably become an important tool for personalized prescription.
authors.affiliation: Psychiatric Clinic Ljubljana, 1260 Ljubljana Polje, Slovenia. blanka.kores@psih-klinika.si
authors.forename: Blanka Kores
authors.initials: BK
authors.lastname: Plesnicar
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D007206:Individuality; D010597:Pharmacogenetics; D010641:Phenotype; D057285:Precision Medicine; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D012565:Schizophrenic Psychology; D012931:Social Environment; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6